Weikai Biotechnology

Shanghai Weikai Biotechnology is a leading life sciences company specializing in the development and production of high-performance biological reagents and raw materials for the biopharmaceutical industry. The company serves as a critical upstream supplier for the mRNA vaccine, cell therapy, and gene therapy sectors, providing essential enzymes such as T7 RNA polymerase, mRNA capping enzymes, and inorganic pyrophosphatase. In addition to bioprocessing materials, Weikai offers a broad portfolio of products for In Vitro Diagnostics (IVD) and high-performance cosmetic ingredients. By leveraging its proprietary enzyme engineering and directed evolution platforms, the company aims to localize the supply of critical nucleic acid synthesis materials within the Chinese market. Weikai has secured significant investment from prominent firms like Sequoia China and IDG Capital to expand its GMP manufacturing capacity and global R&D footprint.